These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1430194)

  • 1. Cancer risks from germline p53 mutations.
    Frebourg T; Friend SH
    J Clin Invest; 1992 Nov; 90(5):1637-41. PubMed ID: 1430194
    [No Abstract]   [Full Text] [Related]  

  • 2. [Li-Fraumeni syndrome].
    Frebourg T
    Bull Cancer; 1997 Jul; 84(7):735-40. PubMed ID: 9339200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Germline mutations of the p53 gene].
    Frebourg T
    Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.
    Gonzalez KD; Noltner KA; Buzin CH; Gu D; Wen-Fong CY; Nguyen VQ; Han JH; Lowstuter K; Longmate J; Sommer SS; Weitzel JN
    J Clin Oncol; 2009 Mar; 27(8):1250-6. PubMed ID: 19204208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline mutations of the p53 tumor-suppressor gene in cancer-prone families: a review.
    Soussi T; Leblanc T; Baruchel A; Schaison G
    Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):33-6. PubMed ID: 8511038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer risks from germ line tumor suppressor gene mutations.
    Frebourg T; Malkin D; Friend S
    Princess Takamatsu Symp; 1991; 22():61-70. PubMed ID: 1844252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline TP53 R337H mutation is not sufficient to establish Li-Fraumeni or Li-Fraumeni-like syndrome.
    Ribeiro RC; Rodriguez-Galindo C; Figueiredo BC; Mastellaro MJ; West AN; Kriwacki R; Zambetti GP
    Cancer Lett; 2007 Mar; 247(2):353-5; author reply 356-8. PubMed ID: 16750598
    [No Abstract]   [Full Text] [Related]  

  • 8. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome.
    Wu CC; Shete S; Amos CI; Strong LC
    Cancer Res; 2006 Aug; 66(16):8287-92. PubMed ID: 16912210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Li-Fraumeni syndrome and germ-line mutations of the p53 gene].
    Leblanc T; Soussi T
    Arch Pediatr; 1994 Jan; 1(1):61-70. PubMed ID: 8087224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.
    Birch JM; Hartley AL; Tricker KJ; Prosser J; Condie A; Kelsey AM; Harris M; Jones PH; Binchy A; Crowther D
    Cancer Res; 1994 Mar; 54(5):1298-304. PubMed ID: 8118819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene.
    Varley JM; Thorncroft M; McGown G; Appleby J; Kelsey AM; Tricker KJ; Evans DG; Birch JM
    Oncogene; 1997 Feb; 14(7):865-71. PubMed ID: 9047394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome.
    Tabori U; Malkin D
    Cancer Res; 2008 Apr; 68(7):2053-7. PubMed ID: 18381406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel p53 splice site mutations in three families with Li-Fraumeni syndrome.
    Verselis SJ; Rheinwald JG; Fraumeni JF; Li FP
    Oncogene; 2000 Aug; 19(37):4230-5. PubMed ID: 10980596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there anticipation in the age at onset of cancer in families with Li-Fraumeni syndrome?
    Trkova M; Hladikova M; Kasal P; Goetz P; Sedlacek Z
    J Hum Genet; 2002; 47(8):381-6. PubMed ID: 12181637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 mosaicism with an exon 8 germline mutation in the founder of a cancer-prone pedigree.
    Kovar H; Auinger A; Jug G; Müller T; Pillwein K
    Oncogene; 1992 Nov; 7(11):2169-73. PubMed ID: 1359493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.
    Palmero EI; Achatz MI; Ashton-Prolla P; Olivier M; Hainaut P
    Curr Opin Oncol; 2010 Jan; 22(1):64-9. PubMed ID: 19952748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
    Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
    Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
    Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
    Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for germline p53 mutations in pediatric and adult patients of high-risk groups in Poland.
    Fiszer-Maliszewska L; Czernik J; Sawicz-Birkowska K; Perek D; Kozera M; Wojciechowska B; Kazanowska B; Hudziec P; Kilar E
    Arch Immunol Ther Exp (Warsz); 2000; 48(4):309-15. PubMed ID: 11059649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline TP53 mutations and Li-Fraumeni syndrome.
    Varley JM
    Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.